Background The balance of risk and benefi t from early neurosurgical intervention for conscious patients with superfi cial lobar intracerebral haemorrhage of 10-100 mL and no intraventricular haemorrhage admitted within 48 h of ictus is unclear. We therefore tested the hypothesis that early surgery compared with initial conservative treatment could improve outcome in these patients.
Introduction
Spontaneous supratentorial intracerebral haemorrhage is a heterogeneous disorder with clinical manifestations that range from none to rapid death. It aff ects 4 million patients worldwide each year and median case fatality at 1 month is 40%. 1 Many survivors remain severely disabled and therefore are an enormous burden on stroke services with only a quarter having a good outcome. 2 Surgery has the potential to reduce the volume of intracerebral haemorrhage and there is clinical and experimental evidence that mass removal might reduce nervous tissue damage, possibly by relieving local ischaemia [3] [4] [5] [6] or removal of noxious chemicals. [7] [8] [9] Nevertheless, responses to surgery do not seem to be homogeneous, with trial data, expert opinion, and mechanistic reasoning all indicating that early surgery benefi ts only some clots. For example, large, surgically accessible clots exerting a mass eff ect might benefi t from early surgery; whereas inaccessible clots, with surgical approach paths that cross eloquent speech and motor regions probably do not. Therefore, most neurosurgeons would remove a large frontopolar intracerebral haemor rhage with recent deterioration in consciousness and would not remove a small intracerebral haemorrhage in the internal capsule or basal ganglia. Also some clots are too small or the patient is too well to consider intervention. The hypothesis in the present STICH II study was based on the results of a subgroup analysis from the fi rst STICH trial that accorded with these ideas. 10 Several prospective randomised controlled trials [11] [12] [13] [14] [15] [16] [17] [18] [19] were undertaken during the previous century, cul minating in the fi rst large trial of early surgery for spontaneous supratentorial intracerebral haemor rhage, 20 the results of which were neutral. This outcome seemed to occur because some groups of patients did worse with surgery (those with deep-seated bleeds or with intraventricular haemorrhage and hydrocephalus) and some better (patients with superfi cial lobar haematomas without intraventricular haemorrhage). 10 The same eff ect was noted in a meta-analysis of other studies: a benefi t with surgery that was not signifi cant. 21 These fi ndings led to the STICH II trial, designed to fi nd out whether early surgery would improve outcomes compared with initial conservative treatment in patients with superfi cial lobar supratentorial intracerebral haemor rhage without intraventricular haemorrhage. The hypothesis was that early surgery could improve outcome in conscious patients in whom there is a superfi cial intracerebral haemorrhage of 10-100 mL and no evidence of intraventricular haemorrhage.
Methods
Trial design and participants STICH II was an international, multicentre, prospective, randomised, parallel group, pragmatic trial as described in the protocol. 21 129 neurosurgical units in 39 countries completed all regulatory requirements and registered for participation in this trial.
For the UK, ethics approval was obtained from the Scotland Multicentre Research Ethics Committee and the Newcastle and North Tyneside Local Research Ethics Committee. Elsewhere, appropriate local ethical approval was sought from each participating centre and the trial was undertaken according to the UK Medical Research Council's good clinical practice guide lines and local ethical and research and development procedures.
Patients were eligible if they had a spontaneous lobar intracerebral haemorrhage on CT scan (≤1 cm from the cortical surface of the brain) with a volume of between 10 mL and 100 mL, were within 48 h of ictus, had a best motor score on the Glasgow Coma Score (GCS) of 5 or 6, and had a best eye score of 2 or more (ie, were conscious at randomisation). They were ineligible if the haemorrhage was due to an aneurysm or angiographically proven arteriovenous malformation; was secondary to tumour or trauma; involved the basal ganglia, thalamic, cerebellar, or brainstem regions; or if there was any intraventricular blood. Patients were also ineligible if they had any severe pre-existing physical or mental disabilities or comorbidities that could interfere with the assessment of the outcome.
Interventions
Patients were randomly allocated to either early surgery or initial conservative treatment. In the early surgery group, surgeons were expected to endeavour to undertake evacuation of the haematomas within 12 h. In the initial conservative treatment group, delayed evacuation was permitted if judged clinically appropriate. All patients were given the best medical treatment as defi ned according to their hospital settings.
Information about the preintracerebral haemorrhage status and early progress of all patients (including GCS and focal signs for the fi rst 5 days) was gathered by the local investigator at 2 weeks, discharge, or death, whichever was earliest. Surviving patients had an additional CT scan at 5 days (give or take 2 days) to assess changes in the haematoma size with and without surgery. Patients' general practitioners (UK) or their local investigators (outside the UK) were then contacted at 4 months after randomisation to confi rm that the patients were alive, their place of residence, and to request completion of a major events form.
Randomisation and masking
The Centre for Healthcare Randomised Trials, Aberdeen, UK, provided an automatic telephone and internet-based randomisation service to assign patients in a 1:1 ratio. Patients were stratifi ed by country group and planned operation (craniotomy or other) and within these strata they were allocated according to a minimisation algorithm based on age (<60 years, 60-69 years, or ≥70 years) and neurological defi cit in the worst aff ected arm or leg (normal, weak, or paralysed) with a random component such that there was a 20% chance of the allocation being reversed.
Patients, relatives, and site investigators were aware of which treatment the patient had been allocated to; however, at the coordinating centre only the data manager was aware of the allocation. Throughout the study, data broken down by treatment assignment were never provided to investigators or to the study team. Outcome was assessed with questionnaires that were completed by the patients or their relatives. If it was necessary to administer these questionnaires to the patients then the interviewer was masked to treatment allocation. Outcome assignment, data cleaning, and CT assessment were all completed before the treatment assignment was unmasked.
Outcomes
The primary outcome was a prognosis-based favourable or unfavourable outcome dichotomised from the Extended Glasgow Outcome Scale (GOSE) at 6 months after random isation. GOSE was computed from the answers to 14 questions in a postal questionnaire completed by patients or their relatives. 22 The postal questionnaires were trans lated into the appropriate languages and mailed to patients or their relatives or carers at 5 months after random isation and, if needed, followed with a reminder at 6 months. In the centres where there were problems with the postal systems, there were likely to be literacy or lan guage problems, or when there had been no response to a reminder, questionnaires could be completed by a social worker or research nurse, who did not know the treat ment allocation, in interview with the patient or relative.
The prognosis-based outcome was designed as a diff erential type of outcome with two diff erent levels of success. 23 The prognostic score was based on GCS, age, and haemorrhage volume at randomisation, and the algorithm had been developed from patients with a broad range of diff erent intracerebral haemorrhages. It was calculated as:
× GCS -age -0·64 × volume
The predefi ned cutoff of 27·672 24 for supratentorial intracerebral haemorrhage was used to divide the patients into a poor prognosis group and a good prognosis group. The outcome was judged favourable if GOSE was good recovery or moderate disability;
For the trial protocol see http:// www.trialsjournal.com/ content/12/1/124 additionally, in the poor prognosis group, upper severe disability. This disability represents patients who are completely self-caring within their homes but who are unable to shop or use public transport without assistance. Secondary outcomes were mortality, time to death, prognosis-based dichotomised Rankin (appendix p 4), and GOSE, and Rankin and EuroQoL; all measured at 6 months.
We also report the crossover and major event rates in each treatment group.
Statistical analysis
Based on fi ndings from previous work that a prognosisbased favourable outcome would be noted in 37% of the conservative treatment group, a sample size of 566 (283 in each group) was needed to show a 12% benefi t from surgery (two-sided p<0·05) with 80% power. We therefore proposed a sample size of 600 patients to allow for withdrawals and crossovers.
The independent data monitoring committee reviewed data from the study after 50, 100, 200, and 400 patients had been recruited. These interim reviews were confi dential, with only the data manager and the data monitoring committee having access to them. The committee did not plan any formal interim analyses but worked on the principle that a diff erence of at least 3 SEs in an analysis of a major outcome event (eg, death from all causes or independent survival at 6 months) would be needed to justify halting or modifying the study before the planned recruitment was completed.
The detailed analysis plan has been reported previously. 24 Analysis was undertaken on an intention-totreat basis by treatment allocation. Outcomes were Figure 1 : Trial profi le *One site recruited one patient but had undertaken surgery before randomisation (the patient was allocated to initial conservative treatment); another site recruited three patients, and two of these had surgery before randomisation (one allocated to early surgery and one to initial conservative treatment); because of the severe breach of protocol all four patients were excluded.
See Online for appendix
For EuroQoL see http://www. euroqol.org/eq-5d-products/eq-5d-3l.html reported as odds ratios (OR) with 95% CI. Absolute diff erences with 95% CI were also reported. Primary outcome analysis was a simple categorical frequency comparison by use of the χ² test for prognosisbased favourable and unfavourable outcome on GOSE. Logistic regression was undertaken to adjust for covariates, age, GCS, volume of haematoma, and neurological defi cit.
Secondary analysis consisted of a Kaplan-Meier survival curve with log-rank test, χ² test for mortality at 6 months, and 6 month prognosis-based Rankin. Additionally, GOSE, Rankin, and EuroQoL were reported by treatment allocation.
We also did a sensitivity analysis based on a proportional odds model.
Prespecifi ed subgroup analyses were also undertaken for age (<65 years, ≥65 years), volume of haematoma (≤35 mL, >35 mL), GCS (8) (9) (10) (11) (12) (13) (14) (15) , time from ictus to randomisation (<21 h, ≥21 h), and severity of neurological defi cit in worse limb (normal, weak, paralysed). An additional analysis of the two prognosis groups was undertaken.
This trial is registered, number ISRCTN22153967. For continuous variables, data are median (IQR; range) and mean (SD); for categorical variables, data are number (%). *Data were missing for four patients in the early surgery group who withdrew after randomisation and for one patient in the initial conservative treatment group for whom no 2 week data were obtained. †One patient in the initial conservative treatment group did not provide this information. 
Role of the funding source
Neither the sponsor nor the funder of the study had any role in study design, data gathering, analysis, and interpretation, or writing of the report. The corresponding author and ENR had full access to all the data in the study and all members of the writing committee had responsibility for the decision to submit for publication.
Results
601 patients from 78 centres in 27 countries were randomly assigned between Jan 11, 2007, and Aug 15, 2012: 307 to early surgery and 294 to initial conservative treatment; recruit ment by centre is shown in the appendix p 2. Four patients were excluded because they were recruited by two centres that randomly assigned patients after evacuating the haematoma: a serious protocol violation (fi gure 1). All other patients were included in the analysis irrespective of the decision of the central CT reading committee about their eligibility (the CT committee's fi ndings will be reported later in a separate paper). This analysis, therefore, includes 305 patients assigned to early surgery and 292 to initial conservative treatment (fi gure 1). Table 2 shows the haematoma characteristics reported by site investigators at randomisation. The median volume of the haematoma (with the Broderick method 25 ) was 36 mL (23·0-55·5) and the median depth from the cortex surface was 1 mm (0-2).
Four patients withdrew from the study after allocation to early surgery group because they or their relatives refused surgery and further involvement, and all data for For continuous variables, data are median (IQR; range) and mean (SD); for categorical variables, data are number (%). *Data were missing for one patient in the initial conservative group for whom no forms were returned. For continuous variables, data are median (IQR; range) and mean (SD); for categorical variables, data are number (%). *Minimally invasive procedures were burrhole with endoscopic evacuation in two patients and keyhole evacuation in one patient. †These questions were not answered for patients who were paralysed and sedated at that time and data were not recorded for some other patients. one patient in the initial conservative treatment group were lost by the centre (fi gure 1). Thus, process data were available for 301 patients in the early surgery group and 291 in the initial conservative treatment group. Another patient withdrew (self-discharged) in the early surgery group between 2 weeks and the 6 month follow-up because the patient did not want to have surgery (fi gure 1). Nine patients were lost to follow-up (although six were known to be alive at 6 months and could be included in survival analyses; fi gure 1). Thus, 583 patients had complete follow-up at 6 months for the primary outcome analysis.
Of the 301 assessable patients in the early surgery group, 288 (96%) had surgery and 281 (93%) had surgery within 12 h (table 3) . 13 (4%) patients did not have surgery because their families refused (n=6), or they had a rebleed or intraventricular haemorrhage (3), cardiac problem, respi ratory problem, or fever (3), and logistical problems (1). Of 291 assessable patients in the initial conservative treatment group, 62 (21%) had surgery (table 3) . Reasons for these patients requiring operation were deterioration in GCS (n=36), oedema (1), rebleed (3), deterioration and oedema (7) , deterioration and rebleed (5), deterioration, oedema, and rebleed (4), rise in intracranial pressure (2), surgeon error (1), family request (2), and an underlying cause (1). Craniotomy was the most commonly used surgical technique for evacuation in 343 (98%) of 350 of cases.
Comparison of patients in the initial conservative treatment group who had surgery with those who did not showed that they were more likely to undergo surgery if they had a paralysed limb at randomisation ( At 2 weeks, the status of patients was classifi ed as dead, still on a neurosurgical ward, transferred to another unit or hospital, or discharged. There were signifi cant diff erences between the early surgery group and initial conservative group (p=0·02). In the early surgery group, 16 (5%) of 301 patients had died, 85 (28%) were still on a neurosurgical ward, 80 (27%) were transferred, and 120 (40%) were discharged, whereas in the initial conservative treatment group 29 (10%) of 291 patients had died, 102 (35%) were still on a neurosurgical ward, 60 (21%) were transferred, and 100 (34%) were discharged. Few patients in either group (four [1%] of 301 in the early surgery group and one [<1%] of 291 in the initial conservative treatment group) were treated with factor VIIa. Patients in the initial conservative group were more likely to have an angiogram (108 [37%] of 291 vs 87 [29%] of 301; p=0·034). However, clinically signifi cant lesions were only found in ten patients: three with an arteriovenous malformation and three with an aneurysm in the early surgery group, and three patients with an arteriovenous malformation and one with an aneurysm in the initial conservative treatment group. Post-randomisation adverse events reported during the hospital stay before the 2 week point were similar in the two groups: overall 37 (6%) of 592 patients had a further intracerebral haemorrhage increasing the volume by at least 20% (14 in the early surgery group and 23 in the initial conservative treatment), six (1%) had an ischaemic stroke (fi ve and one, respectively), six (1%) a pulmonary embolism (one and fi ve, respectively), 16 (3%) a major cardiac event (nine and seven, respectively), and 71 (12%) pneumonia (31 and 40, respectively) .
With the prognosis-based dichotomy of GOSE, 123 (41%) of 297 patients in the early surgery group had a favourable outcome at 6 months compared with 108 (38%) of 286 patients in the initial conservative treatment group (OR 0·86, 95% CI 0·62 to 1·20; p=0·367). Early surgery had an absolute benefi t of 3·7% (table 4) and a relative benefi t of 9·7% (-11·4 to 30·8). Adjustment for the covariates age, GCS, haemorrhage volume, and neurological defi cit made little diff erence to the prognosis-based outcome (0·85, 0·59 to 1·22; p=0·384).
The mortality rate at 6 months was 18% in the early surgery group and 24% in the initial conservative treatment group (table 4; OR 0·71, 95% CI 0·48 to 1·06; p=0·095); absolute diff erence in favour of early surgery was 5·6% (table 4) and the relative diff erence was 7·3% (-1·3 to 16·0). The actual survival advantage during the fi rst 6 months with early surgery was not signifi cant (fi gure 2). 27 (9%) of 298 patients died at 30 days and 43 (14%) at 90 days in the early surgery group, whereas 43 (15%) of 291 patients died at 30 days and 63 (22%) at 90 days in the initial conservative treatment group. Table 4 shows the full extended GOSE, Rankin, and EuroQoL by treatment group. The prognosis-based Rankin showed favourable outcome in 47% of the patients in the early surgery group and in 44% of those in the initial conservative treatment group (p=0·46; table 4); the absolute diff erence in favour of early surgery was 3·1% (table 4) and the relative diff erence was 7·0% (95% CI -11·4 to 25·3). The actual distribution of GOSE was more favourable for the early surgery group than for the initial conservative treatment group (fi gure 3), although the diff erence was not signifi cant (p=0·091; table 4). The proportional odds model analysis of these data (OR 0·77, 95%CI 0·58 to 1·03; p=0·075) was consistent with the χ² trend analysis. Figure 4 shows prespecifi ed subgroup analyses and analyses for the poor and good prognosis groups. No prespecifi ed subgroups showed heterogeneity of treatment response.
At 6 months, 79 (39%) of 203 patients in the poor prognosis group died and 67 (33%) had lower severe disability, whereas 44 (12%) of 380 patients died in the good prognosis group and 63 (17%) had lower severe disability. Patients in the good prognosis group were much more likely to have a good recovery (85 [22%] of 380) or moderate disability (89 [23%]) than were those in the poor prognosis group (12 [6%] of 203 and 13 [6%], respectively). Subgroup analysis of the prognosis-based prediction group showed signifi cant heterogeneity (I²=79%, p=0·03). Patients in the poor prognosis group were more likely to have a favourable outcome with early surgery than with initial conservative treatment (OR 0·49, 95% CI 0·26-0·92; p=0·02; fi gure 4). By contrast, there was no advantage for surgery in the good prognosis group (1·12, 0·75-1·68; p=0·57).
There were diff erences in the causes of death between the two groups. Patients in the early surgery group were more likely to die from cardiac events (14 [26%] of 54 vs fi ve [7%] of 69) and less likely to die from intracerebral haemorrhage or rebleed (eight [15%] vs 20 [29%]), chest ) than were those in the initial conservative treatment group. There were an additional 139 serious adverse events reported in 107 patients (appendix p 1), with no diff erences between the treatment groups. The most common adverse events were respiratory infection in eight patients in the early surgery group and 12 in the initial conservative group, intracerebral haemorrhage or rebleed in nine and 12, respectively, neurological deterioration in nine and 17, respectively, seizures in ten and fi ve, respectively, and cardiac events in four and eight, respectively.
Discussion
In STICH II, using the prognosis based outcome, we did not fi nd signifi cant evidence to support our hypothesis that early surgery compared with initial conservative treat ment (with delayed surgery if the patient deterior ates) improves outcome in conscious patients in whom there is a superfi cial intracerebral 
0·86 (0·62-1·20)
0·74 (0·64-0·86)
Fixed odds ratio (95% Cl) haemorrhage of 10-100 mL and no evidence of intraventricular haemorrhage. The prespecifi ed recruitment target was attained in the STICH II trial and a follow-up rate of 98% was achieved at 6 months. Historically, recruitment and power are diffi cult and ubiquitous issues in surgical trials. The proportional odds model is sensitive to diff erences across the outcome scale rather than just to those in the primary dichotomy (favourable or unfavourable). That this analy sis gives a lower p value than the primary outcome suggests insuffi cient power might have been an issue; however, this trial was powered to detect a 12% diff erence in outcome and took 67 months to reach the target sample size. If the 4% diff erence was regarded as clinically signifi cant it would require many more patients.
Interpretation of many surgical trials is also complicated by crossovers from conservative treatment to surgery as commonly seen in spinal, cardiac, and neurosurgical trials. 20, 26, 27 In STICH II, 62 (21%) of 291 patients assigned to initial conservative treatment went on to have delayed surgery. At the time of the delayed surgery, the patients were in deeper coma with worse neurological defi cits than were those in the early surgery group (table 3) . The crossover to surgery from initial conservative treatment might therefore have rescued these patients from what otherwise might have been a fatal outcome, but because of the intention-to-treat analysis they remained in the initial conservative treatment group.
The absence of a signifi cant diff erence between the two groups in this trial might be because of the case mix of patients: more than half were fully conscious or just confused; such patients perhaps could be safely observed and delayed surgery undertaken only if their state deteriorates. There is evidence that the lack of eff ect could be a consequence of surgery being benefi cial for some and not for other patients with an overall average showing little diff erence. In secondary analyses, a survival advantage (with no vegetative survivors) was noted for surgery throughout the 6 month follow-up (fi gure 2), but it was not signifi cant. Mortality rate remained lower with early surgery than with initial conservative treatment throughout. This pattern contrasts with the Kaplan-Meier plot from the fi rst STICH trial in which a more diverse group of patients with intracerebral haemorrhage was examined and there was no diff erence. 20 Because we had dichotomised patients' prognoses as part of the primary outcome in the STICH II trial, we looked at the post hoc eff ects of surgery in the two prognostic groups. Patients in the STICH II trial with a poor prognosis did better with early surgery, whereas those with a good prognosis did not (fi gure 4). The interaction test was signifi cant (p=0·03), but this result needs to be interpreted cautiously because the analysis was not prespecifi ed. However, the result accords with some surgeons' preference to initially observe patients with a good prognosis thus avoiding surgery unless a patient deteriorates later.
Two-thirds of patients in this trial had documented hypertension before the intracerebral haemorrhage. Almost a quarter of these hypertensive patients were not on antihypertensive medication at the time of their ictus.
In STICH II, almost all the patients undergoing surgery had craniotomy. Other operative procedures include decompressive craniectomy and minimal access pro cedures. Use of decompressive craniectomies have been reported for patients with intracerebral haemorrhage 28 but no prospective randomised controlled trials have yet been undertaken to compare their eff ect with conservative treatment. Other minimally invasive techniques are being tested in ongoing trials, in particular stereotactic delivery of tissue plasminogen activator to clots to dis solve them 29 and tissue plasminogen activator assisted clearance of ventricular haemorrhage. 30 Almost half of all intracerebral haemorrhages are associated with intra ventricular haemorrhage and preliminary results from CLEAR IVH, 31 the precursor to CLEAR III, have shown a benefi t for treatment with intraventricular tissue plasminogen activator. In the STICH and STICH II trials, craniotomy was assessed whereas in the CLEAR III and MISTIE trials minimal access techniques were assessed. Figure 5 shows the updated meta-analyses for the trials of surgery for intracerebral haemorrhage and for the subgroup of patients with lobar intracerebral haemorrhage and no intraventricular haemorrhage; the results are discussed in the panel. However, minimal access techniques might be more benefi cial for deeper clots
Panel: Research in context

Systematic review
Previously reported meta-analyses 36, 37 were updated with the addition of data from STICH II after confi rmation that there had been no other reports of trials of surgery versus initial conservative treatment. STICH II is the 15th pragmatic randomised controlled trial of surgery for intracerebral haemorrhage compared with conservative treatment to be reported. STICH II (n=597) is of moderate size compared with occlusive stroke trials but in intracerebral haemorrhage it is second only in size to STICH (n=1033). Incorporation of the results from STICH II (583 patients) with the previous meta-analysis of 14 trials of surgery 37 gives a total sample size of 3366. The result shows a signifi cant advantage for surgery with an odds ratio of 0·74 (95% CI 0·64-0·86; p<0·0001), although there is signifi cant heterogeneity (p=0·0002) because the studies included diff erent patient groups and diff erent types of surgery. Addition of the STICH II data to a previous individual patient data meta-analysis subgroup of patients with a lobar intracerebral haemorrhage and no intraventricular haemorrhage 38 did not show evidence of heterogeneity (p=0·21) but there was still not a signifi cant benefi t from surgery (n=923; 0·78, 0·59-1·02; p=0·07).
Interpretation
The results of the meta-analyses suggest that there is a role for surgery in patients with intracerebral haemorrhage, but that there is still some uncertainty about which patients benefi t most. The STICH studies diff er from the other trials in that early surgery was compared with the option of delayed surgery for patients who later deteriorate. The survival advantage for conscious patients with lobar haematomas seems to be greatest when the prognosis is poorer (Glasgow Coma Score 9-12) and when randomly assigned within 21 h. This slight advantage is lost in patients with a better prognosis perhaps because there is time to observe them initially and only operate in those that later deteriorate. and intraventricular haemorrhage. Further research is warranted to assess the benefi ts of these other surgeries.
The results of STICH II confi rm that early surgery does not increase the rate of death or disability at 6 months and might have a clinically relevant survival advantage for patients with spontaneous superfi cial intra cerebral haemor rhage without intraventricular haemorrhage.
